Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- 3 Major Wholesalers Acknowledge Illegal Diversion of Ethical Drugs to Wholesalers
October 28, 2014
- Xtandi Receives Positive CHMP Opinion for Treatment of Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer: Astellas
October 28, 2014
- Univ. of Tokyo, Pfizer Sign Strategic Partnership Deal for Drug Discovery Research
October 28, 2014
- Pfizer Japan Gearing Up for Reorganization in December, Pres. Umeda to Double as Head of New Unit
October 28, 2014
- PII Study Confirms Efficacy of Restless Legs Syndrome Treatment: Hisamitsu
October 28, 2014
- OTC Market Grew to 793 Billion Yen in 2013: Yano Research Institute
October 27, 2014
- Japan Arm of Hengrui Medicine Files Campto Generic for Approval
October 27, 2014
- Astellas Revises Package Insert for Xtandi Following Confirmation of Clinical Benefits in PIII Study
October 27, 2014
- Takeda Gains Worldwide Exclusive Rights for Amitiza Excluding Japan and China from Sucampo
October 24, 2014
- Toray Licenses Hemodialysis Pruritus Treatment to Orient EuroPharma in Taiwan
October 24, 2014
- Global Pharma Market to Reach US$1.3 Trillion by FY2018: IMS Official
October 23, 2014
- Taiho Receives Fast Track Designation from US FDA for Lonsurf
October 23, 2014
- US FDA Accepts sNDA for Fycompa: Eisai
October 23, 2014
- Taisho Files NDA for Anti-Inflammatory Analgesic Patch for Osteoarthritis
October 23, 2014
- Obesity Drug Contrave Hits US Pharmacy Shelves: Takeda
October 23, 2014
- MTPC Downwardly Revises Half-Year, Full-Year Sales Forecasts
October 23, 2014
- Takeda Tops Physician Honoraria Payment List in FY2013
October 22, 2014
- Fujifilm to Ratchet Up Avigan Production for Ebola Treatment
October 21, 2014
- Shionogi Cuts Half-Year Net Profit Projection on Back Taxes
October 21, 2014
- Janssen Files Velcade in Japan for Mantle Cell Lymphoma
October 21, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…